EDITORIAL article
Front. Aging Neurosci.
Sec. Parkinson’s Disease and Aging-related Movement Disorders
Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1642793
This article is part of the Research TopicA comprehensive look at biomarkers in neurodegenerative diseases: from early diagnosis to treatment response assessmentView all 24 articles
Editorial: A comprehensive look at biomarkers in neurodegenerative diseases: from early diagnosis to treatment response assessment
Provisionally accepted
- 1IRCCS Carlo Besta Neurological Institute Foundation, Milan, Italy
- 2Universita di Pavia, Pavia, Italy
- 3Ng Teng Fong General Hospital, Singapore, Singapore
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Neurodegenerative diseases (NDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), pose an escalating global health crisis, affecting millions worldwide and placing an immense burden on healthcare systems (GBD 2021 Nervous System Disorders Collaborators, 2024). A shared hallmark of many NDs is the misfolding, aggregation, and accumulation of specific proteins in the brain, events that often precede the onset of clinical symptoms (Sweeney et al., 2017). The identification and validation of reliable biomarkers that can detect these underlying pathological processes are crucial for improving diagnosis, predicting disease progression, and monitoring the efficacy of therapeutic interventions. This Research Topic brings together a collection of original research articles and reviews that significantly contribute to our understanding of the aging brain and the mechanisms underlying NDs.The studies encompass a range of methodologies, from molecular investigations to clinical assessments and computational analyses, offering a multifaceted perspective of the role of different biomarkers across a wide spectrum of NDs, including tauopathies, synucleinopathies, prion diseases, and other proteinopathies associated with dementia and cognitive impairment.Early and accurate diagnosis remains a critical goal in managing neurodegenerative conditions, particularly AD, where pathological changes such as amyloid-β accumulation and tau pathology begin many years before the onset of clinical symptoms. Detecting these molecular alterations at the preclinical or prodromal stage is essential not only for enabling timely intervention and care planning but also for the effective recruitment and stratification of participants in clinical trials of disease-
Keywords: Alzheimer's disease, Parkinson's disease, cognitive impairment, Dementia, diagnosis, risk factor, molecular mechanism
Received: 07 Jun 2025; Accepted: 10 Jun 2025.
Copyright: © 2025 Pascuzzo, Palesi, Wan and Cazzaniga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Riccardo Pascuzzo, IRCCS Carlo Besta Neurological Institute Foundation, Milan, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.